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Post-polypectomy bleeding (PPB) is one of the most common complications of endoscopic polypectomy. There are multiple risk 
factors related to patient and polyp characteristics that should be considered. In most cases, immediate PPB can be effectively managed 
endoscopically when recognized and managed promptly. Delayed PPB can manifest in a myriad of ways. In severe delayed PPB, 
resuscitation for hemodynamic stabilization should be prioritized, followed by endoscopic evaluation and therapy once the patient 
is stabilized. Future areas of research in PPB include the risks of direct oral anticoagulants and of specific electrosurgical settings for 
hot-snare polypectomy vs. cold-snare polypectomy, benefits of closure of post-polypectomy mucosal defects using through-the-scope 
clips, and prospective comparative evaluation of newer hemostasis agents such as hemostatic spray powder and over-the-scope clips. 
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INTRODUCTION
Colonoscopy with polypectomy is the gold standard for 
removing precancerous polyps of the colon. The process of 
identification and removal of polyps during colonoscopy has 
been demonstrated to decrease the risk of colon cancer devel-
opment in individuals.1 However, polypectomy during colo-
noscopy carries risks, including post-polypectomy bleeding 
(PPB), post-polypectomy syndrome, and perforation. PPB can 
be categorized into two groups: immediate PPB and delayed 
PPB. In immediate PPB, the endoscopist can almost always 
identify a bleeding complication at the time of polypectomy 
and perform endoscopic therapy at that time. Delayed PPB 
usually manifests hours to days after colonoscopy, with the 
patient presenting with signs or symptoms of hematochezia, 
acute blood loss anemia with possible hemodynamic instabili-
ty, and end-organ damage (acute kidney injury, syncope, chest 
pain, dyspnea, etc.). A patient with significant hematochezia 
hours to days after colonoscopy should always raise a suspi-
cion for delayed PPB. Although similar bleeding complica-
tions can occur after resection of polyps in the foregut, this re-
view will focus on the current approaches in the management 
of PPB resulting from polypectomy in the colon.
RISK FACTORS
A number of patient-specific and polyp-specific risk factors 
have been identified in association with polypectomy (Table 1). 
A large study (including 15,285 colonoscopies) on PPB re-
sulting from colonoscopies, performed as part of the English 
National Health Service Bowel Cancer Screening Programme, 
demonstrated the rate of PPB to be 0.4% per colonoscopy per-
formed in patients at a high risk of colon polyps (positive fecal 
occult blood stool test).2 A systematic review and meta-anal-
ysis of studies on colorectal neoplastic lesions ≥20 mm that 
were managed with endoscopic polypectomy demonstrated 
that in 6,474 colonoscopies with large-polyp polypectomy, the 
rate of bleeding was 6.5%, which was significantly higher than 
that for small-polyp polypectomy.3
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A study by Kim et al. that included 5,152 patients under-
going colonoscopy (in which >9,000 polyps were removed) 
showed multiple risk factors for immediate PPB.4 Polyp-based 
multivariate analysis showed that age ≥65 years, comorbid 
cardiovascular or chronic renal disease, anticoagulant use, 
polyp size >1 cm, laterally spreading polyp, thick polyp stalk, 
poor bowel preparation, and inadvertent cutting of a polyp 
before the intended application of current were all significant 
risk factors of PPB.4
A large study by Zhang et al. that included 15,553 polypec-
tomies showed multiple risk factors for delayed PPB.5 Polyp 
size >10 mm (odds ratio [OR], 4.6; 95% confidence interval 
[CI], 2.9–7.2), immediate PPB (OR, 2.9; 95% CI, 1.4–5.9), 
and colon polyp pathology (juvenile polyp: OR, 4.3; 95% CI, 
1.8–11, Peutz-Jegher polyp: OR, 3.3; 95% CI, 1.0–10.7) were all 
associated with increased rates of PPB.5 Another recent case–
control study demonstrated that polyp size and location in 
the colon were independent risk factors for delayed PPB.6 The 
risk of bleeding increased by 13% for every 1 mm increase in 
polyp diameter. Polyps located in the right colon were more 
likely to bleed than those in the left colon or rectum (OR, 4.7; 
95% CI, 1.9–11.6).6 A study of the English National Health 
Service Bowel Cancer Screening Programme supported these 
findings.7 Of 130,831 colonoscopies with 167,208 polypecto-
mies, the major risk factors for PPB were cecal location and 
increasing polyp size.7 After adjustment for polyp size, the OR 
of PPB for a cecal polypectomy was found to be 13.5 (95% CI, 
3.9–46.4).7
Uninterrupted antiplatelet agents (APAs) and anticoagu-
lant medications have also been associated with higher rates 
of PPB. A recent systematic review and meta-analysis of 11 
studies (with 9,307 patients) showed that use of aspirin and/
or nonsteroidal anti-inflammatory drugs (NSAIDs) was not a 
risk factor for immediate PPB (OR, 1.1; 95% CI, 0.6–2.1), but 
increased the risk of delayed PPB (OR, 1.7; 95% CI, 1.2–2.2).8 
Furthermore, there is evidence of an increased risk of PPB 
while on clopidogrel treatment (OR, 9.7; 95% CI, 3.1–30.8) 
and with the combination of clopidogrel + aspirin (dual anti-
platelet therapy) and/or NSAIDs (OR, 3.4; 95% CI, 1.3–8.8).9 
Studies have demonstrated increased rates of PPB in both the 
immediate and delayed settings.10 There have been reports of 
PPB rates as high as 22% in cases of colonoscopy with polyp-
ectomy performed with prophylactic clip closure in patients 
who are on heparin bridge anticoagulant therapy (compared 
with the rate of 1.9% in patients not on heparin bridge thera-
py in this study).11 Similar risks of delayed PPB with heparin 
bridge therapy have also been noted in other studies.12,13 A 
higher risk of PPB (51.7%) was noted in patients undergoing 
endoscopic mucosal resection (EMR) while on heparin bridge 
therapy.14 Continued warfarin use has also previously been 
found to have an increased risk of PPB (OR, 13.4; 95% CI, 
4.1–43.7).15 Increased costs of hospitalization have also been 
reported in association with heparin bridge therapy. A recent 
study16 showed a 10-fold higher risk of PPB in patients on 
heparin bridge anticoagulation therapy than in those on inter-
rupted warfarin therapy. Other risk factors for PPB were also 
identified and found to be similar to those reported in other 
studies (Table 1).17
With the advent of newer APAs and direct oral anticoag-
ulants (DOACs) over the past few years, there has been an 
increasing need to study the effects of these agents on PPB 
and to identify risk factors that predispose patients to PPB. A 
study by Beppu et al. has shown that edoxaban (a direct factor 
Xa inhibitor) had the lowest PPB rate among the four current 
DOACs on the market and the use of DOACs (interrupted 1 
day before the treatment procedure and restarted within 24 h 
after the procedure in this study) carried a similar safety pro-
file, decreased the rate of delayed PPB, and reduced the length 
of hospital stay, compared with heparin bridge therapy.18 A 
similar study by Yanagisawa et al.19 showed comparable rates 
of delayed PPB between warfarin and all DOACs (no patients 
on edoxaban). Predictive models for PPB in patients receiv-
ing warfarin and DOACs, such as the Outcomes Registry for 
Better Informed Treatment score20 and a risk-scoring model 
from China,21 have been proposed but are yet to be validated 
for widespread use. There are also studies reporting the risk of 
PPB with hot-snare (thermal) polypectomy (HSP) and cold-
snare (nonthermal) polypectomy (CSP) in the background of 
APAs, warfarin, and DOACs, which are detailed in the next 
section. Overall, comprehensive prospective studies assessing 
the risk of PPB associated with newer APAs and DOACs are 
Table 1. Risk Factors Associated with Polypectomy
Polyp size (>10 mm)
Pedunculated polyp with a thick stalk
Polyp pathology (juvenile polyp, Peutz-Jegher polyp)
Polyp location in the right colon (a cecal location carries the 
highest risk)
Patient age ≥65 yr
Comorbid cardiovascular or chronic renal disease
Warfarin, DOACs
Aspirin/NSAIDs
P2Y12 receptor antagonists (e.g., clopidogrel)
GPIIb/IIIa inhibitors (e.g., abciximab)
PAR-1 inhibitors (e.g., vorapaxar)
Heparin bridge anticoagulation therapy
DOACs, direct oral anticoagulants; NSAID, nonsteroidal anti-in-
flammatory drug; PAR-1, protease-activated receptor-1.
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lacking and need to be addressed in the immediate future.
PREVENTION OF POST-POLYPECTOMY 
BLEEDING
In patients taking APAs and anticoagulant medications, 
withholding these medications in the peri-colonoscopic peri-
od can pose significant risks of thrombo-embolic and cardiac 
events. Thus, the risk of withholding these medications must 
be carefully weighed against that of PPB. A review by Baron et 
al.22 on the management of antithrombotic therapy in patients 
undergoing invasive procedures in all specialties was pub-
lished in 2013, which classified nonthermal polypectomy (CSP) 
of small colonic polyps (<10 mm) as a low-risk procedure 
and thermal polypectomy (HSP) of large polyps (≥10 mm) 
as well as EMR as high-risk procedures. The review made 
appropriate recommendations about the discontinuation and 
resumption of APAs and anticoagulants based on the bleeding 
risk of the procedure and risk of thrombo-embolic events on 
discontinuation of antithrombotic therapy. Thereafter, spe-
cific guidelines have been issued by the American Society for 
Gastrointestinal Endoscopy (ASGE)23 and the British Society 
of Gastroenterology/European Society of Gastrointestinal En-
doscopy (ESGE),24 both in 2016, regarding the peri-procedural 
management of antithrombotic medications specifically for 
gastroenterological procedures. Both sets of guidelines have 
classified polypectomy (thermal and nonthermal) and EMR 
as high-risk procedures and have risk-stratified the indications 
for antithrombotic medications. Based on the risk assessment 
of indications for antithrombotic therapy, the risk of throm-
bo-embolic events on discontinuation, characteristics (phar-
macokinetics and pharmacodynamics) of individual agents, 
and comorbidities of individual patients, recommendations 
have been provided for currently approved APAs and antico-
agulants with respect to the timing of discontinuation before 
the procedure, need for heparin bridging, and timing of re-
sumption after procedure completion. The guidelines also ad-
vise caution in high-risk indications for antithrombotic ther-
apy and recommend liaising with the prescribing specialist 
(cardiologist, neurologist, etc.) regarding the timing of discon-
tinuation. The two sets of guidelines are similar with respect 
to polypectomy, with the ASGE providing expanded recom-
mendations on individual DOACs based on the patient’s cre-
atinine clearance. Experts recommend using these guidelines 
to create individual plans for patients based on their individu-
al characteristics and comorbidities. The guidelines published 
by the Japan Gastroenterological Endoscopy Society in 2013,25 
with an update in 2017 specifically addressing DOACs,26 and 
those published by the Asian Pacific Association of Gastro-
enterology/Asian Pacific Society for Digestive Endoscopy27 in 
2018 have also provided similar recommendations.
There has been significant interest in the past few years in 
the individual bleeding risk associated with polypectomy of 
small (<10 mm), large (10–19 mm), and very large (≥20 mm) 
polyps; in the individual bleeding risk associated with thermal 
polypectomy (HSP) and nonthermal polypectomy (CSP); and 
in modalities that can be deployed at the time of polypectomy 
to prevent immediate and/or delayed PPB.
There is evidence of a lower rate of delayed PPB with CSP 
than that with HSP. Individual studies28,29 and systematic 
reviews and meta-analyses30 have shown that although HSP 
minimizes immediate PPB through thermal therapy, it carries 
a risk of damage to the deeper tissues and blood vessels, lead-
ing to delayed PPB. CSP, on the other hand, is associated with 
immediate PPB that can be treated at the time of polypectomy 
and with much lower delayed PPB rates. Meanwhile, the two 
techniques have comparable resection rates. A recent study31 
showed that the depth and size of the mucosal defect on the 
day after polypectomy was greater with HSP than with CSP, 
and this finding may also partially account for the higher rates 
of delayed PPB with HSP. The decision to use HSP is primarily 
determined by the polyp size and morphology (pedunculated 
vs. nonpedunculated). Most polyps encountered during colo-
noscopy are either diminutive (<5 mm) or small (6–9 mm) 
nonpedunculated polyps. The current ESGE guidelines32 
recommend CSP as the preferred technique for the removal 
of subcentimeter (<10 mm) polyps, with a recent meta-anal-
ysis33 supporting this recommendation. A recent multicenter 
randomized controlled trial34 showed that CSP is not inferior 
(comparable resection rate) to HSP for small nonpedunculat-
ed polyps with a superior safety profile (lower delayed PPB 
rate). These findings were also supported by a recent me-
ta-analysis35 that did not include the randomized controlled 
trial.34 There has been a concerted effort to expand the use 
of CSP to large nonpedunculated polyps (≥10 mm). Recent 
systematic reviews and pooled-analyses36,37 showed excellent 
rates of resection comparable to those of HSP, with lower rates 
of delayed PPB than those of HSP. There were higher rates of 
immediate PPB with polyps ≥20 mm, which were effectively 
managed during the procedure.
Expanding the application of CSP to small pedunculated 
polyps (≤10 mm) has also been considered, with a recent 
study38 showing low rates of immediate PPB in procedures 
involving endoscopic clipping and showing no delayed PPB. 
Further studies are required to assess the safety of CSP for 
pedunculated polyps. The general practice remains HSP for 
pedunculated polyps, given that penetrating blood vessels 
within the stalk is not uncommon.
As previously mentioned, the presence of antithrombotic 
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medications (APAs, warfarin, DOACs) further adds complex-
ity to determining the safety of CSP and HSP and the rates of 
associated immediate and delayed PPB. Several studies39-41 and 
a prospective, multicenter, randomized controlled trial42 have 
shown the safety of CSP for subcentimeter nonpedunculated 
polyps (<10 mm) in the presence of continued use of APAs, 
warfarin, and DOACs with no increased risk of delayed PPB 
compared with HSP,43 even when multiple antithrombotic 
agents44 were continued.
There is controversy about whether clipping mucosal de-
fects (Fig. 1) after polypectomy (HSP and CSP) may reduce 
the risk of subsequent delayed PPB. In a study of 524 large 
polyps (≥2 cm) in which 47.1% were not clipped and the 
others were clipped, there was a significantly decreased risk 
of delayed PPB in the group with prophylactic clipping of re-
section sites (1.8% clipped vs. 9.7% not clipped).45 Multivariate 
analysis showed that the absence of clipping (OR, 6.0; 95% CI, 
2.0–18.5), a location proximal to the splenic flexure (OR, 2.9; 
95% CI, 1.1–8.1), and polyp size were all associated with de-
layed PPB.45 A subsequent multicenter randomized controlled 
study of prophylactic clipping vs. nonclipping polypectomy 
sites in polyps <2 cm showed no significant difference be-
tween the two groups, suggesting a lack of benefit with clip-
ping mucosal defects for polyps <2 cm.46 More recent studies 
have also reported similar findings, showing that prophylactic 
clipping of mucosal defects following polypectomy of nonpe-
dunculated polyps <20 mm and irrespective of location has 
not been effective in reducing the risk of delayed PPB, and is 
associated with higher costs with no definite benefits.47,48 In a 
recent multicenter, randomized trial of 1,900 patients under-
going polypectomy of large nonpedunculated colon polyps 
(≥20 mm), endoscopic clip closure of the mucosal defect was 
found to reduce the risk of PPB (3.3% vs. 9.6%) and the risk 
reduction appeared to be largely limited to polypectomies 
performed in the proximal colon.49 In contrast, in a separate 
randomized trial in 1,098 patients undergoing polypectomy of 
nonpedunculated polyps ≥10 mm, there was no benefit with 
closure of mucosal defects using prophylactic endoscopic 
clipping in reducing the rate of delayed PPB, and this finding 
was consistent with that obtained for large polyps (≥20 mm).50 
Several systematic reviews and meta-analyses51-56 have consis-
tently shown a similar lack of benefit of prophylactic endo-
scopic clipping of mucosal defects of nonpedunculated polyps 
up to 19 mm, with inconclusive benefits for nonpedunculated 
polyps ≥20 mm. This heterogeneity in polyps ≥20 mm could 
be due to variations in the polyp location that have not been 
accounted for in most studies, as was reported in the previ-
ously mentioned randomized trial49 in which a benefit was 
noted only in the proximal colon. A recent study57 proposed 
the use of a Doppler endoscopic probe to detect superficial 
(<4 mm) arterial blood flow in the post-polypectomy mucosal 
defect to identify lesions that would benefit from prophylac-
tic endotherapy (clipping, thermal therapy) and showed that 
mucosal defects ≥15 mm more likely contain arterial blood 
flow. Defects with arterial flow have a much higher risk of 
delayed PPB and may benefit from prophylactic endotherapy. 
This technology appears to be promising in detecting high-
risk lesions and would need further prospective study before 
widespread implementation can be recommended. Another 
study proposed thermal therapy of visible vessels seen after 
EMR, with the results showing no benefit in the reduction of 
delayed PPB, supporting our previously mentioned hypothesis 
that delayed PPB primarily results from damage to vessels in 
deeper tissues during HSP. To avoid injury to deeper tissues in 
A B
Fig. 1. (A) Colonic mucosal defect status after endoscopic mucosal resection (EMR). (B) Multiple endoscopic through-the-scope clips is deployed to close the EMR 
mucosal defect.
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HSP, a recent study58 compared the two most commonly used 
electrocautery settings and found no difference in the rates of 
resection or rates of delayed PPB.
Previous studies have suggested a potential benefit of per-
forming prophylactic submucosal injection of an epinephrine 
solution before polypectomy.59,60 These studies, however, have 
been limited by their small size. A more definitive prospective, 
randomized multicenter trial of prophylactic injection of epi-
nephrine solution before the resection of large colon polyps 
(>10 mm) showed no significant difference in the immediate 
or delayed PPB rates in patients who received submucosal in-
jection of epinephrine solution.61
Given the increased risk of immediate PPB associated with 
large pedunculated polyps with thick stalks, some endosco-
pists routinely place a detachable snare (endoloop) around 
the stalk of a large pedunculated polyp before polypectomy. 
In a prospective, randomized study on the placement of a 
detachable snare on the stalk of a pedunculated polyp com-
bined with injection of epinephrine solution compared with 
sole injection of epinephrine solution, there was a signifi-
cantly decreased risk of immediate PPB in the combination 
group treated with detachable snare compared to the group 
given epinephrine injection alone.62 A systematic review and 
meta-analysis recently demonstrated that both prophylactic 
mechanical therapy and injection therapy reduced immediate 
PPB, but had no effect on delayed PPB. The combination of 
both therapies, however, was not significantly better than ei-
ther therapy alone.63
MANAGEMENT OF POST-POLYPECTOMY 
BLEEDING
The management of immediate PPB is relatively straight-
forward, if detected and addressed at the time of polypec-
tomy. Every polypectomy resection site should be routinely 
examined after resection to check for the presence of muscle 
tissue (deep) injury, perforation, residual polyp, or bleeding. In 
the case of minimal oozing of blood from a polypectomy site 
(Fig. 2), a small period of observation with water lavage often 
results in self-limited cessation of oozing. Further, in cases 
of slow oozing after polypectomy, the mucosal defect can be 
gently and directly suctioned with the scope tip for 30–60 s. 
This direct pressure on small bleeding capillaries often results 
in effective hemostasis.
When a more brisk or persistent immediate PPB is encoun-
tered, it is essential to have an effective field of view. For this, a 
water jet on the colonoscope is helpful, to allow for continued 
lavage of the bleeding site in order to identify the precise lo-
cation of the bleeding source. Identifying a bleeding source is 
important for the targeted deployment of endoscopic therapy. 
The most commonly utilized option for significant immediate 
PPB is the use of through-the-scope (TTS) clips. In previous 
studies, the rate of endoscopic success with TTS clips has been 
high, with cessation of bleeding achieved in the vast majority 
of patients.64,65 In the series by Parra-Blanco et al.,65 there were 
no cases of recurrent bleeding.
The preferred method for deploying a clip in treating bleed-
ing from the stalk of a pedunculated polyp is by deploying the 
clip perpendicular to the base of the stalk to ligate the feeder 
vessels.66 For PPB occurring after sessile polyp removal, the 
goal is to directly tamponade the underlying blood vessel by 
maneuvering the clip and opposing the mucosa on both sides 
of the defect, when possible.67 For very large endoscopic resec-
tion, the adjacent mucosal margins may not be approximated 
effectively at times. To ensure hemostasis, the area should be 
lavaged copiously while the TTS clip is closed but not de-
ployed. If the area has no re-accumulation of red blood, then 
clip deployment is appropriate in that position.67
Other methods of endoscopic hemostasis include direct 
thermal therapy, which is performed with bipolar cautery, 
snare tip, or thermal probes. In addition, for refractory oozing 
PPB, coagulation therapy with argon plasma coagulation can 
be applied to the resection bed. The electrosurgical settings 
vary depending on the preference of the provider and the 
system used; however, generally, caution should be exercised 
when performing thermal therapy in the right colon and 
cecum, given the thin colonic wall in the region.68 There are 
no head-to-head prospective studies comparing thermal ther-
apy to TTS clips for the management of PPB. The decision 
to use a certain method will depend on the clinical scenario, 
available equipment, and preference of the endoscopist. For 
Fig. 2. Scant oozing from the mucosal resection site after cold-snare polypec-
tomy.
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instance, intraprocedural bleeding during large-polyp EMR 
can be effectively treated with snare-tip soft coagulation 
(STSC). This avoids the placement of TTS clips and/or larger 
thermal defects that can, at times, impair the effective com-
pletion of a large-polyp EMR. If STSC is not adequate, then 
intraprocedural bleeding during a large-polyp EMR can often 
be achieved using coagulating forceps. These techniques have 
been described in detail by Klein and Bourke.69
For either immediate or delayed PPB, if standard hemostasis 
therapies including TTS clip application, epinephrine solution 
injection, thermal/coagulative therapy, and/or combinations 
thereof do not achieve hemostasis, there are newer hemostasis 
products available that can be utilized. The over-the-scope clip 
(OTSC; Ovesco Endoscopy, Tubingen, Germany) has been 
more extensively studied in the treatment of upper gastroin-
testinal bleeding but has also been demonstrated to be an ef-
fective salvage therapy option in patients with PPB.70-73 More-
over, contact hemostasis powder spray (Hemospray; Cook 
Medical, Bloomington, IN, USA) has been used to successful-
ly treat PPB.74-77 Given that hemostasis powder will slough off 
some interval after treatment, studies76,77 have shown higher 
rates of re-bleeding within the first 72 h and that re-bleeding 
is more likely to occur with an actively spurting bleed and 
with a background of hemodynamic instability. It is, therefore, 
recommended to use Hemospray as a temporary bridge to a 
more definitive treatment and to repeat colonoscopy in 24–48 
h after achieving initial hemostasis to perform definitive en-
doscopic therapy.
In cases of delayed PPB, the site of active bleeding can be 
endoscopically determined by repeating a colonoscopy or 
nonendoscopically via angiography or red blood cell nuclear 
scintigraphy.78 Although most cases of delayed PPB can be 
effectively managed endoscopically, the decision to proceed 
with colonoscopy and the timing of colonoscopy should be 
individualized. First, the patient should be assessed for hemo-
dynamic instability (including orthostasis) and the duration, 
frequency, and volume of hematochezia, in addition to labora-
tory evaluation with complete blood count and prothrombin 
time/international normalized ratio. Resuscitation of blood 
volume and infusion of crystalloid to achieve hemodynamic 
stability should be prioritized.
Sonnenberg79 conducted a decision analysis study and 
showed that proceeding with colonoscopy for delayed PPB 
was beneficial in identifying and treating a bleeding lesion 
in 22% of the cases, with a number needed to treat of 4.5 
patients. The author concluded that it would be beneficial to 
attempt a repeat colonoscopy, but, at the same time, it is rea-
sonable to manage some patients expectantly. In a study by 
Derbyshire et al., the requirement for blood transfusion and 
a drop in hemoglobin of >2 g/dL were predictors of the need 
for a therapeutic intervention.2 Ma and Bourke proposed an 
algorithm for the management of bleeding after large-polyp 
EMR.67 In this algorithm, the authors recommended bowel 
preparation and colonoscopy for patients with ongoing bleed-
ing, and found that the factors associated with poor outcome 
were American Society of Anesthesiologists grade ≥2, hemo-
dynamic instability, hourly or more frequent hematochezia, 
low admission hemoglobin (<12.0 g/dL), or the requirement 
for blood transfusion.67 Generally, an expedited bowel prepa-
ration followed by expeditious diagnostic and therapeutic 
colonoscopy once a patient is stabilized is appropriate. When 
the culprit polypectomy site is found, we recommend clear-
ing the area of any residual blood and blood clot in order to 
identify the precise source of bleeding within the polypecto-
my defect. The area can be subsequently treated with clips or 
forceps coagulation or some combination with epinephrine 
injection.67,68,80 In general, extensive thermal therapy is dis-
couraged in a post-polypectomy resection site to avoid the 
risk of delayed perforation, as the mucosal resection site is 
often ulcerated. As mentioned previously, the use of OTSCs or 
hemostatic powder can be considered for refractory bleeding 
lesions. For patients that remain hemodynamically unstable 
despite resuscitative efforts, consultations for urgent interven-
tional radiology evaluation and/or urgent surgical evaluation 
are prudent.
CONCLUSIONS
PPB is one of the most common complications of endo-
scopic polypectomy. There are multiple risk factors related to 
patient and polyp characteristics that should be considered. In 
most cases, immediate PPB can be effectively managed endo-
scopically when recognized and managed promptly. Delayed 
PPB can manifest in a myriad of ways. In severe delayed PPB, 
resuscitation for hemodynamic stabilization should be prior-
itized, followed by endoscopic evaluation and therapy once 
the patient is stabilized. CSP for sessile polyps <20 mm seems 
to be safe and has a lower incidence of delayed PPB. Future 
areas of research in PPB include the risks of DOACs, risks of 
specific electrosurgical settings (HSP vs. CSP), and prospective 
comparative evaluation of newer hemostasis agents (hemo-
static spray powder, OTSC, etc.).
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